Lescol® (fluvastatin sodium), is a water-soluble cholesterol lowering agent which acts through the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.
Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol
(see National Cholesterol Education Program (NCEP) Treatment Guidelines, below).
Lescol® (fluvastatin sodium) and Lescol® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate.
In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures.
Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels.
Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded.
Published Studies Related to Lescol (Fluvastatin)
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. [2011.07]
The acute-phase response (APR) to aminobisphosphonates is triggered by activation of gammadelta T cells, resulting in pro-inflammatory cytokine release... In conclusion, intravenous zoledronic acid induced pro-inflammatory cytokine release and APR symptoms in the majority of study participants, which was not prevented by co-administration of fluvastatin.
Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study. [2011.04]
OBJECTIVE: Early arterial wall changes are already present in the apparently healthy, middle-aged population and continuously progress with age. The aim of our study was to investigate whether 30 days low-dose fluvastatin treatment could improve and reverse these arterial changes that are primarily associated with ageing, in otherwise healthy middle-aged males... CONCLUSIONS: We found that subtherapeutic low-dose fluvastatin (10mg daily; 30 days) considerably improves and reverses early functional and morphological arterial wall impairments that are present in apparently healthy, middle-aged males. It might be supposed that such a new and original approach could be valuable in cardiovascular prevention. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. 
It is well established that statins improve the prognosis of patients with coronary artery disease. However, it is still unclear whether the protective effects of statins relate to lipid lowering alone or whether other pleiotropic effects may contribute... These results suggest that high-dose fluvastatin might have pleiotropic effects of potential clinical benefit, and that the combination of ezetimibe with a reduced dose of fluvastatin may also significantly improve endothelial function with reduction of LDL-C and RLP-C.
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. [2010.11]
BACKGROUND AND OBJECTIVES: This open, prospective, randomized trial aimed to assess the effects of statins in chronic kidney disease patients on optimized antiproteinuric treatment with combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade... CONCLUSIONS: In chronic kidney disease patients with residual proteinuria despite combined angiotensin-converting enzyme inhibitor and angiotensin receptor blockade therapy, add-on fluvastatin does not affect urinary proteins, but further reduces serum lipids and is safe. Whether combined angiotensin-converting enzyme inhibitor, angiotensin receptor blockade, and statin therapy may improve cardiovascular outcomes in this high-risk population is worth investigating.
Effects of fluvastatin therapy on serum interleukin-18 and interleukin-10 levels in patients with acute coronary syndrome. [2010.06]
CONCLUSION: Inflammation plays an important role in the initiation of acute coronary syndromes. Fluvastatin possesses an anti-inflammatory effect, independent of its lipid-lowering action.
Clinical Trials Related to Lescol (Fluvastatin)
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia [Recruiting]
This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended
Release Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in
LDL-C lowering from baseline to week 12 (endpoint) in patients with primary
hypercholesterolemia or mixed dyslipidemia at moderate or high CV risk who did not achieve
their lipid goals when treated with Fluvastatin sodium Immediate Release Capsules 40 mg QD.
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C [Recruiting]
This study seeks to evaluate the safety and efficacy of taking fluvastatin along with
peginterferon alfa in previous partial responders with genotype 1 HCV.
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer [Recruiting]
RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the
laboratory may help doctors learn how fluvastatin effects biomarkers related to breast
PURPOSE: This randomized phase II trial is studying how fluvastatin effects biomarkers in
women undergoing surgery for ductal carcinoma in situ or stage I breast cancer.
Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-Menopausal Women With Low Bone Mass [Completed]
This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of
occurrence and the severity of post dose symptoms that may occur during the 3 day period
following a zoledronic acid infusion in post menopausal women with low bone mass.
Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone [Completed]
The objective of this study is to assess the effect of the combination treatment on
C-reactive protein and inflammatory markers as well as the safety and tolerability in a
Reports of Suspected Lescol (Fluvastatin) Side Effects
Acute Respiratory Distress Syndrome (12),
Eosinophilic Pneumonia (12),
Pain in Extremity (4),
Muscular Weakness (4),
Respiratory Failure (4),
Fall (3), more >>
Page last updated: 2011-12-09